Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 315 publications
A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy.
Journal: Journal of pain research
Published: July 04, 2025
Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system.
Journal: PloS one
Published: June 09, 2025
Assessing the association between drug use and ischaemic colitis: a retrospective pharmacovigilance study using FDA Adverse Event data.
Journal: BMJ open
Published: May 21, 2025
Label-free morphology-based phenotypic analysis of spinal and bulbar muscular atrophy muscle cell models.
Journal: Disease models & mechanisms
Published: November 21, 2024
The impact of headache specialist density and the introduction of gepants and lasmitidan on prescriptions for acute migraine treatments: a regression and interrupted time series analysis.
Journal: Frontiers in neurology
Published: November 19, 2024
Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database.
Journal: The journal of headache and pain
Published: October 15, 2024
Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
Journal: BMJ (Clinical research ed.)
Published: September 18, 2024
Rizatriptan as an Over-the-Counter Triptan in the Treatment of Migraine Attacks.
Journal: Pain and therapy
Published: May 12, 2024
Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy.
Journal: CNS drugs
Published: April 15, 2024
Recent Development of Zolmitriptan Formulation in Migraine Therapy: Production, Metabolism and Pharmaceutical Aspects.
Journal: CNS & neurological disorders drug targets
Published: April 05, 2024
The 5-HT1B and 5-HT1D agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans.
Journal: Handbook of clinical neurology
Published: February 02, 2024
Last Updated: 10/31/2025